Cardiovascular and Renal Drugs Advisory Committee
Committee Meeting on February 23, 2012 from 8:00 a.m. to 5:00 p.m.
Agenda: The committee will discuss new drug application (NDA) 203202, proposed trade name NORTHERA (droxidopa capsules), submitted by Chelsea Therapeutics, Inc., for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure (Parkinson''''s Disease, Multiple System Atrophy, and Pure Autonomic Failure), Dopamine Beta-Hydroxylase Deficiency, and Non-Diabetic Autonomic Neuropathy.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment